GLP-1 RA on Liver OMICS in MASLD

Not yet recruiting

• Conditions: NAFLD; Diabetes; Obesity
• Interventions: Drug: GLP-1 receptor agonist

• Registration Number: NCT06982378
• Lead Sponsor: Medical College of Wisconsin

Brief Summary

In patients with type II diabetes mellitus (T2DM) and obesity, an excess plasma-free fatty acid is found with an associated increased lipid accumulation in adipocytes and liver tissue. Lipid droplet accumulation in the hepatocytes is an initial step in the development of metabolic dysfunction associated steatotic liver disease (MASLD. Insulin resistance, which is associated with T2DM, mediates the inflammation of these lipids, resulting in the progression of MASLD to metabolic dysfunction associated steatotic hepatitis (MASH). Hence, in T2DM, obesity, and MASLD, changes in the lipid profile occur, and they are interrelated.

In this study, we aim to assess improvement in the lipidomic, its associated metabolic changes and evaluate the co-regulated genes in the liver tissue among patients with MASLD with intervention with GLP-1 RA, which has shown to benefit T2DM and obesity.

Detailed Description

The study involves patients with a diagnosis of MASLD by histology and have diabetes/obesity. The 'omics' ( lipidomics, proteomics, metabolites, and inflammatory profiles and transcriptomics) data of liver tissue and plasma of patients will be compared between patients who have received 1 year of GLP-1 treatment with those who did not have GLP-1 agents.

The study will evaluate the changes in different 'omics' and metabolites in the liver tissue following the use of GLP-1 agents in these patients

Study Timeline

• Status Verified: 2025-05
• Study First Submitted: 2025-05-13
• Study First Submitted QC: 2025-05-13
• Last Update Submitted: 2025-05-13
• Study First Posted: 2025-05-21
• Last Update Posted: 2025-05-21
• Study Start: 2025-07
• Primary Completion: 2026-12
• Study Completion: 2026-12

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• known diagnosis of MASLD by histology, also have diabetes/ obesity
• on treatment with GLP-1 RA at stable dose

Exclusion Criteria

• unable to have a liver biopsy, recent change in medication for diabetes or hyperlipidemia
• on immunosuppression, liver or kidney transplant
• pregnancy

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Had GLP-1 RA treatment	GLP-1 receptor agonist	Patients with MASLD and obesity/diabetes - on GLP-1 RA as a standard of care treatment

Primary Outcome Measures

Name	Time	Method
Changes in lipidomics profile on use of GLP-1 RA	1 year

Secondary Outcome Measures

Name	Time	Method
Changes in associated proteomics and transcriptomics with the use of GLP-1 RA	1 year

Trial Locations

Locations (1)

Froedtert Hospital; 🇺🇸 Milwaukee, Wisconsin, United States